BioCardia News

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced

GlobeNewswireMay 9 07:00 ET

Express News | BioCardia Announced The Primary Endpoint Results Of The Open Label Roll-in Cohort Of The Cardiamp Cell Therapy In Chronic Myocardial Ischemia Trial

BenzingaMay 1 07:16 ET

Express News | BioCardia Announces Results From Open Label Roll-In Cohort Of Patients Having Chronic Myocardial Ischemia With Refractory Angina; Showed Avg. Increase In Exercise Tolerance Of 107 Seconds And An Avg. Of 82% Reduction In Angina Episodes At The Primary Six-

BenzingaMay 1 07:15 ET

BioCardia Reveals Promising CardiAMP Trial Results in Webcast

TipRanksMay 1 07:12 ET

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the

GlobeNewswireMay 1 07:00 ET

Express News | BioCardia Completes Enrollment Of CardiAMP Cell Therapy For Treatment Of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BenzingaApr 25 09:01 ET

Express News | BioCardia Completes Enrollment of Cardiamp Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-in Cohort

ReutersApr 25 09:00 ET

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in

BenzingaApr 22 07:38 ET

BioCardia(BCDA.US) Officer Buys US$1,012.83 in Common Stock

$BioCardia(BCDA.US)$ Officer Altman Peter purchased 2,750 shares of common stock on Apr 19, 2024 at an average price of $0.3683 for a total value of $1,012.83.Source: Announcement What is statement of

moomoo NewsApr 19 18:19 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO

BenzingaMar 29 08:06 ET

BioCardia Full Year 2023 Earnings: Misses Expectations

Yahoo FinanceMar 29 06:11 ET

BioCardia(BCDA.US) Officer Buys US$195 in Common Stock

$BioCardia(BCDA.US)$ Officer Altman Peter purchased 500 shares of Common Stock on Mar 28, 2024 at an average price of $0.39 for a total value of $195.Source: Announcement What is statement of changes

moomoo NewsMar 28 20:14 ET

Q4 2023 BioCardia Inc Earnings Call

Yahoo FinanceMar 28 05:58 ET

Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference

The following is a summary of the BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript:Financial Performance:BioCardia's revenues fell to $0.5 million in 2023 from $1.4 million in the previous year

moomoo AIMar 27 21:16 ET · Conference Call

BioCardia: Q4 Earnings Insights

BioCardia (NASDAQ:BCDA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:00 AM.Here's what investors need to know about the announcement.EarningsBioCardia beat estimated earnings by

BenzingaMar 27 16:10 ET

BioCardia Q4 EPS $(0.09) Beats $(0.11) Estimate, Sales $13.00K Miss $90.00K Estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.75 percent increase over losses of $(0.16) pe

BenzingaMar 27 16:06 ET

BioCardia 2023 Loss/Shr 55c >BCDA

BioCardia 2023 Loss/Shr 55c >BCDA

Dow JonesMar 27 16:01 ET

Press Release: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia(R), Inc. [Nasdaq: BCDA], a developer of c

Dow JonesMar 27 16:00 ET

Express News | BioCardia Ended 2023 With Cash And Cash Equivalents Of $1.1M

Moomoo 24/7Mar 27 14:04 ET

Earnings Scheduled For March 27, 2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. • REE Automotive (NASDAQ:REE) is estimated to repor

BenzingaMar 27 05:02 ET